Get started

Biotechnology

SRZN a Penny biotech LONGSRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful for liver metabolic disorders from a genetic basis. SRZN has been trending up for a week with a bit of a pause in the middle of it. It picked up 60% of its price while breaking out through the anchored VWAP lines and the volume profile. The far greater market is the former. It is priced at 90 or more off it's all-time high of about $160. IF it picks up hype from the last clinical trial getting a report and a calendared review by the, SRZN could reach for that all time high. This is speculative and risky as are most biotechnology penny stocks. They are trading news and potential not current net revenues. A small position with room in the stop loss for the average range and volatility is best. This is a typical high risk higher potential reward type of trade.
NASDAQ:SRZNLong
by AwesomeAvani
Pioneering Cancer Treatment with QINLOCK and VimseltinibIntroduction Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is at the forefront of developing innovative cancer treatments, with a keen focus on leveraging their proprietary switch-control kinase inhibitor platform. The company has made significant strides, particularly with its flagship product, QINLOCK, and the promising pipeline candidate vimseltinib, aiming for a transformative year in 2024. Revenue and Profit Forecasts Deciphera has projected an optimistic financial trajectory for 2023, with preliminary unaudited revenue for the fourth quarter estimated at approximately $47 million and full-year revenue expected to be around $162 million. This growth is largely attributed to the robust sales of QINLOCK, which alone contributed roughly $46 million in net product revenue in Q4 2023. The company's financial health is further underscored by its substantial cash reserves, amounting to approximately $352 million as of the end of 2023, ensuring operational and capital expenditure funding well into the second half of 2026​​​​. Growth Drivers The continued expansion and commercial success of QINLOCK in treating gastrointestinal stromal tumor (GIST) patients, along with the strategic rollout of vimseltinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT) and potential applications in chronic graft versus host disease (cGVHD), underscore Deciphera's growth trajectory. The company's strategic partnerships, such as the distribution agreement with GENESIS Pharma for QINLOCK in Central and Eastern Europe, are pivotal to its international market expansion​​​​. Recent Financial Performance Deciphera's earnings in Q4 2023 beat analyst expectations, reporting an EPS of -$0.54 against the anticipated -$0.58. This performance reflects a 32.9% increase in quarterly revenue year-over-year, indicating strong commercial execution and market acceptance of its products. Analysts remain optimistic about the company's future earnings, projecting gradual EPS improvement through 2025​​. Technical and Market Outlook Deciphera's technical indicators and market sentiment appear positive, buoyed by recent financial results and the potential for its pipeline candidates. The company's strategic focus on developing first-in-class and best-in-class treatments for cancer positions it well within the biopharmaceutical sector for sustained growth and innovation​​​​. Conclusion Deciphera Pharmaceuticals is poised for significant growth in 2024 and beyond, driven by its innovative product portfolio, strategic market expansions, and strong financial position. With QINLOCK's continued success and the anticipated commercial launch of vimseltinib, Deciphera is on the cusp of evolving into a self-sustaining, multi-product company. As it advances its mission to improve the lives of people with cancer, the biopharmaceutical firm remains a compelling entity within the oncology space, promising exciting developments for investors and patients alike. ---------------- NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
DLong
by olimchik
ROIV - BioTech reporting 2/13 as a LONG earnings tradeRoivant Scientes, on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, ROIV gained 38% in 2023 but has been down 4 %YTD. The volume and volatility show both are heightened in the pre-earnings run- up. The last report in November was a double beat which is good prognosis for the one upcomings. This is a risky earnings play, ROIV does not yet make money. However, because it lost less than forecasted, buyer interest has increased. The call option for 2/16 for a strike of $12.50 is priced at $ 5.00 per contract. I suspect a long trade in shares may gain to $ 11.50 targeting the double top at the turn of the year for a projected gain upside of about 7% (with a stop loss of 2.5%). Considering that ROIV has gained 12% this past week, 7% in the next two days is about the same trend angle. As to the call contract, I have considered 100% return as my expections for the two days before the earnings. If earnings disappoint trader expectations and price fades I will sell to close the contract. If earnings is as expected, I will roll the contract forward into the March monthly and add a bit more capital into the trade.
NASDAQ:ROIVLong
by AwesomeAvani
1
INBS pumped on earnings crush= Watching for LONG maybeINBS crush earnings and went parabolic on an earnings beat. Basically, revenues fell but with belt-tightening and good CEO actions it bled less cash than expected. The tourniquet is working. The post-earnings pump was followed by a flush to the mid-Fib 0.5 support. Trader's got their reward and called it a weekend before lunch. The chop index fell into the consolidation zone and the MACD turned bearish. See the 5 minute chart image inserted to the left. The RSI lines are about 50 maybe with a crossdown impending. I have this on watch for a reversal up. Much will depend on general market strength on Monday. Biotechnology is projected as a hot sector now. This stock was among the hottest of the day. Hoping for a bullish continuation knowing that a trend down is likewise possible.
NASDAQ:INBS
by AwesomeAvani
2
RYTM Biotech Penny Anti-Obesity LONGRYTM did a 120% run in November and December and then pivoted to start the year. It competes in the anti-obesity drug space which is all the rage right now and has snack food manufactures freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382 retracement level and then pivoting into a reversal in the past week. The dual TF RSI shows the resurgence of bullish momentum. Earnings were okay, but not great. An FDA approval to add to the mix of meds and lower their price in the competition may send RHYTHM into launch mode. RYTM did 10% today such is the life of highly volatile penny stocks in what is considered to be the likely hottest sector of the year. I will look toward OTM call options for February 16th presently priced at about $200 per contract and a couple of shares shorted to provide some hedging. Looking for 100% in 2-3 weeks. Will close 1/2 the position a few days before upcoming earnings.
NASDAQ:RYTMLong
by AwesomeAvani
1
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidation, NBIX appears poised for further growth, with technical indicators suggesting a bullish trend ahead. The recent surge in NBIX's stock price comes on the heels of strong performance and positive sentiment surrounding the company's products and pipeline. With a focus on innovative treatments for neurological and endocrine disorders, Neurocrine Biosciences has established itself as a leader in the biopharmaceutical industry, attracting investors seeking exposure to high-growth sectors. Technical analysis reveals that NBIX's current breakout is accompanied by the formation of a bull flag pattern, a bullish continuation pattern that often precedes further upward movement. This consolidation phase following a prolonged uptrend suggests that NBIX may be gearing up for another leg higher, providing an attractive entry point for investors. To capitalize on this potential opportunity, traders are advised to monitor the 4-hour time frame closely, watching for confirmation of the breakout and additional upside momentum. A sustained move above the current resistance levels could signal further strength in NBIX's stock price, potentially leading to a retest of its previous all-time highs. Investors considering a position in NBIX should also keep an eye on key support levels and market dynamics, as volatility in the broader market could impact the stock's trajectory. However, with a strong track record of growth and a robust pipeline of innovative therapies, NBIX appears well-positioned to weather any short-term fluctuations and deliver long-term value to shareholders. In conclusion, Neurocrine Biosciences Inc. is breaking out of its all-time highs, presenting a compelling buying opportunity for investors. With 14 years of upward momentum behind it and a bullish pattern forming, NBIX looks poised for further growth in the coming weeks and months. By monitoring the 4-hour time frame and remaining vigilant for additional breakouts, investors can position themselves to capitalize on the potential upside in NBIX's stock price.
NASDAQ:NBIXLong
by UnknownUnicorn2319099
IGMS a cash burning biotechnology stock SHORTIGMS is down about 70% YTD with no end is sight as the cash burn is greater than the analyst's estimates.On the 2H chart, the midline of the Bollinger Bands has had a persistent negative slope. Overall, IGMS is very shortable if shares can be found at a low cost. I will watch for a correction of the upgoing price toward the middle of the Bollinger Bands especially on a lower time frame such as 30-60 minutes and then target the bottom of the Bollinger Bands on the daily chart for an estimated 25-30% profit. The entry would be at the confluence of the POC line and then BB midline as a bounce down from that resistance. This will be a great trade if S & P / SPY makes a deeper correction than already seen. There was an opportunity one week ago and I think it will come again.
NASDAQ:IGMSShort
by AwesomeAvani
SLB a rising biotechology stock LONGSLN has appreciated 70% in the past month largly on the strength of an earnings beat. Unlike many small cap biotechnology companies, SLN is actually making money and beating analyst's estimates. On the 3O minute chart, price is just below the POC line of the near term volume profile and sitting on the dynamic support of a VWAP line. Strength lines are above 50 and the low time frame green line is above its counterpart. Ovreall, I see SLN rising more after a little more consolidation. I will enter a long trade with a buy stop at 9.18 to catch a trade when price crosses over the POC line, I will set the stop loss at 9.14 below that line and target both 20% and 30% ROI in equal halves of the position.
NASDAQ:SLNLong
by AwesomeAvani
FULC fades after a big move for a SHORT tradeFULC a biotechnology firm with a mixed earnings report early in the month just printed a big move and then stalled at the NY lunch - hour and faded. Will the fade continue or will there be an upward continuation? The 15 -minute chart seems to suggest a downtrend: 1, The volume profile shows heavy trading at the top. This could be short sellers and late-coming long trades. Once a trend down is underway, the short sellers will begin to take profits buying to cover while the long trades will sell at a loss. Probably at this level there will be more longs exiting than shorts until a substantial fall dictates the latter to buy to cover. 2. New short sellers will pile into the trade pushing price down while few new long traders will participate in accelerating the move down. 3. The relative strength on that indicator falling confirms the trend as does the Average Positive Directional Index falling with the combined falling as well. 4. The mass index indicator documents a reversal Accordingly, I will take a short trade and assist the trend down in my own little way. I may take a trade of 100 shares and then sell a call option. In the meanwhile, I will take a put option striking $5.00 for September 15th. I expect a decent realized profit from these trades in this at least currently high volatility biotechnology penny stock.
NASDAQ:FULCShort
by AwesomeAvani
NKTR High Tight Flag- Pre-Earnings High Flyer LONGNKTR is due for earnings on August 8th. The price from the opening bell on the 7th pump nearly 100% to over $1.00 and then faded by a couple of cents. The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity action into a high tight type bull falg which is often considered to be predictive of another leg up of similar magnitude. I will be watching this in the premarket upcoming and also at the report of earnings. I hope to catch a decent ride. If I do get it I will quit the ride as soon as the indicators flip signals. This could be a good one. Buyer anticipation and sentiment could yield great profit in little time the money is exposed to the market.
NASDAQ:NKTRLong
by AwesomeAvani
3
BIOL- running earnings 8/10 LONGBIOL had a triple top in late July so this is a logical long target at 8,0, With earnings in less than two days, volumes above the mean in the past couple of days and a decent price-volume product trend coupled with a Price Monetum Oscillator without any signs of topping out in a momentum stall or fade. I see this as a long pre-earnings play with about 12% upside to the target from the current price. BIOL has no options. The last earnings were a solid cash making top and bottom line beat. Go BIOL !
BLong
by AwesomeAvani
AADI - NASDAQ PENNY Biotech pre-earnings LONGAADI has earnings in two day. On the 30 minute chart, it is significantly below the highs of May and June where it was in a wide ranged consolidation. After that in July price trended down along the support of the second lower VWAP line into a reversal on August 1 shich also ascended the VWAP lines. Upcoming earnings are in two days on the 9th. Prior two earning reports lightly beat the top and bottom lines. This small biotechnology company is making money unlike many of its cash-burning peers. The zero-lag MAC shows a line cross under the histogram which flipped red to green as the lines rise. With this confirmation, I will take a long trade into the earnings. There is no alternative in a call option in this case. From the chart, targets are 6.9, 6.9, and 8.0 over a stop loss of 5.45. I expect this trade to be finished in 4 days or less.
NASDAQ:AADILong
by AwesomeAvani
1
AMRX Biotech earnings Today LONGAMRX is a penny biotechnology stock with earnings out on the Friday the 4th. As you can see on the 15 minute chart, it took off out of consolidation on Wednesday afternoon in a burst of price volume and volatility into an ascending parallel channel. I will buy the stock in the pre-market attempting to exploit the momentum going into earnings. If there is a miss, I will quickly liquidate and instead buy put options expiring on 8/18 striking $ 5 and get as many as 100 of them. This will be a highly risky trade albeit with a comparable reward. I will position to 0.05% of my account cash balance and no more.
ALong
by AwesomeAvani
FLMD biotechology rising post earningsFLMD had earnings in May with positive earnings beating the expectation of analysts that it would continue to lose quarter after quarter. Investors and traders have reacted with a 80% run-up in the month after those earnings. On the 30-minute chart besides the consistent uptrend with minor corrections, what stands out for me is the increasing volumes relative to volumes before the last earnings report. Off the chart, I find information that insider trading with buying more shares on top of existing holdings leads me to believe that this company expects increasing revenues and sustained earnings.
NASDAQ:LFMDLong
by AwesomeAvani
EBS a biotech company focused on vaccinesEBS is a small biotechnology company whose forte is the clean processing and manufacturing facility that the FDA requires for certain bioprocessing to be certified for delivery of products to end-user patients. It is not a research facility like the one in China that accidentally released COVID and the global impact will be likely felt for another decade. EBS does depend on federal support and income from contract work from vaccine manufacturers. There is reasonable expectation or persistent and consistent revenues ongoing without fail unless the FDA decertified the facilities. On the chart, EBS is in a flat bottom triangle on its base. It is presently rising out of the triangle and towards the mean anchored VWAP It is just above The POC line which functions as dynamic support in the demand zone. I see a long trade with the stop loss below the POC line, the first target the blue line representing one standard deviation above the mean VWAP at about 9.4 while the second target is the redline two standard deviations above the mean VWAP at about 10.05 while the final target contemplates that EBS will challenge the high in May of 10.75.
NYSE:EBS
by AwesomeAvani
FULC Biotech Fib Level BouncdFULC on the 15 minute chart had a good response to favorable earnings and then retraced. It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10% price rise in the after-hours which is typically a busy trading period for biotechnology penny stocks. I will take a long trade on FULC in after hours and take off a part of the position in the next trading day and hold the rest through the weekend.
NASDAQ:FULCLong
by AwesomeAvani
VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA process, or well-received research at industry conferences and changing financials within the company. In general, they have a low beta meaning these stocks are not general market responsive and run on their own present or future merits. On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green. I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology trades long with a high R:R due to the inheret risk level.
NASDAQ:VYNE
by AwesomeAvani
VRPX Biotechnology Penny Stock Post EarningsVRPX was on a downtrend from mid-February into a reversal the beginning of May. VRPX beat earnings up still has no cash flow which is very common in this subsector. VRPX is priced on the potential of future earnings. The short and long-moving averages ratio shows bullish momentum also shows strength with an upper Bollinger Band "walk". Price has climbed over the POC line so it is higher than the mean of the share price traded for the duration of the volume profile. I see this as a risky long setup expectant of a 40% profit based on the target of the YTD high in February.
NASDAQ:VRPXLong
by AwesomeAvani
BLUE Biotechnology New Earnings Catalyst LONGBlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks since earnings which is about 500% annualized. GO BLUE. On the daily chart, price was above VWAP and consolidating much of last fall then dropped this YTD until the earnings report of last week. An uptrend is seen after the earnings. This has been a significant reversal sustained over the past month with price rising above the support / demand zone below it. At present, price is one standard deviation below VWAP making it undervalued and ascending. I see this as a risky long trade like many biotechology penny stocks but with a decent probability of profit in consideration of a target of 6.15 which is the top of the long term high volume area. the stop loss is just below the POC line of the volume profile at 3.15 An entry at 4.62 ( limit order above SMA200 (redlne) would yield at profit of 1.50 with a risk of 0.48 making for a R:R of 3:1. Another earnings report is coming up this week. If it is favorable, BLUE could go parabolic to hit the target in a day or two. If not, it will be time to exit the trade.
NASDAQ:BLUELong
by AwesomeAvani
7